Understanding and Overcoming Antibody-Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical...

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) have transformed breast cancer therapy by combining targeted antibodies with potent cytotoxic agents.
• Despite clinical success, acquired resistance frequently limits the long-term efficacy of ADCs in breast cancer treatment.

Purpose of the Study:

• To elucidate the multi-layered mechanisms of ADC resistance in breast cancer, involving tumor-intrinsic and microenvironment factors.
• To explore emerging technologies and therapeutic strategies for overcoming ADC resistance and improving treatment durability.

Main Methods:

• Utilizing cutting-edge technologies like spatial omics, single-cell profiling, and functional genomics.
• Employing patient-derived models to study resistance mechanisms in situ.
• Analyzing dynamic interactions between cancer cells and the tumor microenvironment (TME).

Main Results:

• ADC resistance is a complex process influenced by stromal architecture, vascular heterogeneity, immune modulation, clonal evolution, and pathway reprogramming.
• These factors collectively constrain ADC delivery and therapeutic activity.
• Adaptive signaling networks and phenotypic plasticity contribute significantly to resistance.

Conclusions:

• Understanding the interplay between cancer cells and the TME is crucial for deciphering ADC resistance.
• Emerging strategies include next-generation ADCs, co-targeting compensatory pathways, and biomarker-informed approaches.
• Integrated biological and technological insights pave the way for more durable and personalized ADC-based breast cancer therapies.